2001
DOI: 10.1053/snuc.2001.26205
|View full text |Cite
|
Sign up to set email alerts
|

Evolution of Tc-99m in diagnostic radiopharmaceuticals

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
151
0
10

Year Published

2006
2006
2018
2018

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 217 publications
(161 citation statements)
references
References 132 publications
0
151
0
10
Order By: Relevance
“…Myocardial perfusion imaging with radiotracers is an integral component of the clinical evaluation of patients with known or suspected coronary artery disease (26)(27)(28)(29). Since the early 1980s, intensive research efforts have been directed towards development of cationic 99m Tc complex radiotracers for heart imaging (26,27).…”
Section: Discussionmentioning
confidence: 99%
“…Myocardial perfusion imaging with radiotracers is an integral component of the clinical evaluation of patients with known or suspected coronary artery disease (26)(27)(28)(29). Since the early 1980s, intensive research efforts have been directed towards development of cationic 99m Tc complex radiotracers for heart imaging (26,27).…”
Section: Discussionmentioning
confidence: 99%
“…99m Tc-etarfolatide takes advantage of the more optimal SPECT imaging characteristics of technetium (half-life of 6 h and 140-keV photon) and has been evaluated in several clinical trials (1,3,11,13,16).…”
Section: M Tc-etarfolatide Characteristicsmentioning
confidence: 99%
“…The measurement was carried out every 5th day for a period of 30 days (Banerjee et al, 2001;Kumar et al, 2014b) and % reduction in tumor volume (R) was calculated using following formula Where, Vc and Vt are tumor volume of EAC control group and treated group respectively. Volume was determined by general formula of sphere as where, r1 and r2 are radius from two perpendicular axis of tumor.…”
Section: %Reduction In Tumor Volumementioning
confidence: 99%